Search Results

MAP kinase signaling and inhibition in melanoma.

• Authors : Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.; Flaherty K

Subjects: MAP Kinase Signaling System/MAP Kinase Signaling System/MAP Kinase Signaling System/*genetics ; Melanoma/Melanoma/Melanoma/*enzymology ; Melanoma/Melanoma/Melanoma/*genetics

• Source: Oncogene [Oncogene] 2013 May 09; Vol. 32 (19), pp. 2373-9. Date of Electronic Publication: 2012 Sep 03.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review

• Authors : Tippett, Victoria L.; Tattersall, Luke; Ab Latif, Norain B.

Subjects: Review Article

• Source: Oncogene

Record details

Development of anticancer drugs targeting the MAP kinase pathway.

• Authors : Sebolt-Leopold JS; Pfizer Global Research and Development, Ann Arbor Laboratories, Michigan 48105, USA.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Enzyme Inhibitors/Enzyme Inhibitors/Enzyme Inhibitors/*therapeutic use ; MAP Kinase Signaling System/MAP Kinase Signaling System/MAP Kinase Signaling System/*drug effects

• Source: Oncogene [Oncogene] 2000 Dec 27; Vol. 19 (56), pp. 6594-9.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Print ISSN: 0950-9232

Record details

The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades.

• Authors : Ducret C; Institute de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, 1 Rue Laurent Fries, BP 163, 67404 Illkirch Cedex, France.; Maira SM

Subjects: JNK Mitogen-Activated Protein Kinases* ; Oncogene Proteins*; MAP Kinase Signaling System/MAP Kinase Signaling System/MAP Kinase Signaling System/*physiology

• Source: Oncogene [Oncogene] 2000 Oct 19; Vol. 19 (44), pp. 5063-72.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Print ISSN: 0950-9232

Record details

MUTYH-associated tumor syndrome: The other face of MAP

• Authors : Magrin, Luigi; Fanale, Daniele; Brando, Chiara

• Source: Oncogene; April 2022, Vol. 41 Issue: 18 p2531-2539, 9p

Record details

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

• Authors : Knauf JA; Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA. ; Sartor MA

Subjects: Disease Progression* ; Epithelial-Mesenchymal Transition*/Epithelial-Mesenchymal Transition*/Epithelial-Mesenchymal Transition*/drug effects ; MAP Kinase Signaling System*/MAP Kinase Signaling System*/MAP Kinase Signaling System*/drug effects

• Source: Oncogene [Oncogene] 2011 Jul 14; Vol. 30 (28), pp. 3153-62. Date of Electronic Publication: 2011 Mar 07.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways.

• Authors : Lee SH; Department of Pathobiology, Laboratory of Environmental Carcinogenesis, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA.; Bahn JH

Subjects: MAP Kinase Signaling System*; Activating Transcription Factor 2/Activating Transcription Factor 2/Activating Transcription Factor 2/*physiology ; Activating Transcription Factor 3/Activating Transcription Factor 3/Activating Transcription Factor 3/*genetics

• Source: Oncogene [Oncogene] 2010 Sep 16; Vol. 29 (37), pp. 5182-92. Date of Electronic Publication: 2010 Jun 28.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6

• Authors : Kidger, Andrew M.; Saville, Mark K.; Rushworth, Linda K.

Subjects: Article

• Source: Oncogene

Record details

v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells.

• Authors : Machida K; Department of Molecular Pathogenesis, Nagoya University School of Medicine, Japan.; Matsuda S

Subjects: Antigens, Differentiation* ; Gene Expression Regulation, Viral* ; Genes, src*

• Source: Oncogene [Oncogene] 2000 Mar 23; Vol. 19 (13), pp. 1710-8.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Print ISSN: 0950-9232

Record details

Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase.

• Authors : Hu MC; Department of Cell Biology, Amgen, Inc., Thousand Oaks, California, CA 91320, USA.; Wang Yp

Subjects: Genes* ; MAP Kinase Kinase Kinase 1*; I-kappa B Proteins/I-kappa B Proteins/I-kappa B Proteins/*metabolism

• Source: Oncogene [Oncogene] 1999 Sep 30; Vol. 18 (40), pp. 5514-24.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print Cited Medium: Print ISSN: 0950-9232

Record details